Literature DB >> 30732492

Human challenge models: tools to accelerate the development of malaria vaccines.

Martha M Cooper1, Claire Loiseau1, James S McCarthy2, Denise L Doolan1.   

Abstract

INTRODUCTION: Malaria challenge models, where healthy human volunteers are intentionally infected with Plasmodium species parasites under controlled conditions, can be undertaken in several well-defined ways. These challenge models enable evaluation of the kinetics of parasite growth and clearance, host-pathogen interactions and the host immune response. They can facilitate discovery of candidate diagnostic biomarkers and novel vaccine targets. As translational tools they can facilitate testing of candidate vaccines and drugs and evaluation of diagnostic tests. AREAS COVERED: Until recently, malaria human challenge models have been limited to only a few Plasmodium falciparum strains and used exclusively in malaria-naïve volunteers in non-endemic regions. Several recent advances include the use of alternate P. falciparum strains and other species of Plasmodia, as well as strains attenuated by chemical, radiation or genetic modification, and the conduct of studies in pre-exposed individuals. Herein, we discuss how this diversification is enabling more thorough vaccine efficacy testing and informing rational vaccine development. EXPERT OPINION: The ability to comprehensively evaluate vaccine efficacy in controlled settings will continue to accelerate the translation of candidate malaria vaccines to the clinic, and inform the development and optimisation of potential vaccines that would be effective against multiple strains in geographically and demographically diverse settings.

Entities:  

Keywords:  Malaria; diagnostics; drugs; human challenge models; tools; vaccines

Mesh:

Substances:

Year:  2019        PMID: 30732492     DOI: 10.1080/14760584.2019.1580577

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

Review 1.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 2.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

Review 3.  Monoclonal antibodies for malaria prevention.

Authors:  Maya Aleshnick; Melina Florez-Cuadros; Thomas Martinson; Brandon K Wilder
Journal:  Mol Ther       Date:  2022-04-05       Impact factor: 12.910

4.  The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.

Authors:  Ying Du; Ethan G Thompson; Julius Muller; Joseph Valvo; Jackie Braun; Smitha Shankar; Robert A van den Berg; Erik Jongert; Drew Dover; Jerald Sadoff; Jenny Hendriks; Malcolm J Gardner; W Ripley Ballou; Jason A Regules; Robbert van der Most; Alan Aderem; Christian F Ockenhouse; Adrian V Hill; Ulrike Wille-Reece; Daniel E Zak
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

Review 5.  The promise of mRNA vaccines: a biotech and industrial perspective.

Authors:  Nicholas A C Jackson; Kent E Kester; Danilo Casimiro; Sanjay Gurunathan; Frank DeRosa
Journal:  NPJ Vaccines       Date:  2020-02-04       Impact factor: 7.344

6.  Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.

Authors:  Caroline Barker; Katharine Collet; Diane Gbesemete; Maria Piggin; Daniella Watson; Philippa Pristerà; Wendy Lawerence; Emma Smith; Michael Bahrami-Hessari; Halle Johnson; Katherine Baker; Ambar Qavi; Carmel McGrath; Christopher Chiu; Robert C Read; Helen Ward
Journal:  Wellcome Open Res       Date:  2022-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.